Cargando…

Reasons for discontinuing clozapine: A cohort study of patients commencing treatment

BACKGROUND: Clozapine is uniquely effective in the management of treatment-resistant schizophrenia (TRS). However, a substantial proportion of patients discontinue treatment and this carries a poor prognosis. METHODS: We investigated the risk factors, reasons and timing of clozapine discontinuation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Legge, Sophie E., Hamshere, Marian, Hayes, Richard D., Downs, Johnny, O'Donovan, Michael C., Owen, Michael J., Walters, James T.R., MacCabe, James H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Publisher B. V 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756540/ https://www.ncbi.nlm.nih.gov/pubmed/27211516 http://dx.doi.org/10.1016/j.schres.2016.05.002

Ejemplares similares

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective
por: Legge, Sophie E, et al.
Publicado: (2019)

Clozapine-induced agranulocytosis
por: Mijovic, Aleksandar, et al.
Publicado: (2020)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)

PM381. Reason for clozapine discontinuation
por: Cho, Jin-Woo, et al.
Publicado: (2016)

Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation—Is It Feasible to Develop Evidence-Based Guidelines?
por: Blackman, Graham, et al.
Publicado: (2021)

Clozapine Metabolism is Associated With Absolute Neutrophil Count in Individuals With Treatment-Resistant Schizophrenia
por: Willcocks, Isabella R., et al.
Publicado: (2021)

Clozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study
por: Cho, J., et al.
Publicado: (2018)

Mediation and longitudinal analysis to interpret the association between clozapine pharmacokinetics, pharmacogenomics, and absolute neutrophil count
por: Lock, Siobhan K., et al.
Publicado: (2023)

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study
por: Govind, Risha, et al.
Publicado: (2021)

41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?
por: Bhavsar, Vishal, et al.
Publicado: (2018)

Management of clozapine treatment during the COVID-19 pandemic
por: Gee, Siobhan, et al.
Publicado: (2020)

M212. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Griffiths, Kira, et al.
Publicado: (2020)

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022)

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia
por: Legge, S E, et al.
Publicado: (2017)

Biological Predictors of Clozapine Response: A Systematic Review
por: Samanaite, Ruta, et al.
Publicado: (2018)

Erratum: Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia
por: Legge, S E, et al.
Publicado: (2017)

Erratum: Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia
por: Legge, S E, et al.
Publicado: (2016)

Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records
por: de Freitas, Daniela Fonseca, et al.
Publicado: (2022)

Clozapine treatment and risk of severe COVID‐19 infection
por: Ohlis, Anna, et al.
Publicado: (2021)

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland
por: Ingimarsson, Oddur, et al.
Publicado: (2016)

COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
por: Govind, Risha, et al.
Publicado: (2022)

Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit
por: Barnes, Thomas RE, et al.
Publicado: (2022)

S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Sendt, Kyra-Verena, et al.
Publicado: (2018)

Clozapine haematological monitoring for neutropenia: a global perspective
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2016)

Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis
por: Verbelen, M, et al.
Publicado: (2015)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Ethnic inequalities in treatment with clozapine
por: Fonseca De Freitas, D., et al.
Publicado: (2022)

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations
por: Krivoy, Amir, et al.
Publicado: (2021)

Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis
por: Shirazi, Ayala, et al.
Publicado: (2016)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

S178. SHOULD SCHIZOAFFECTIVE DISORDER DEPRESSED-TYPE BE DISTINCT FROM SCHIZOPHRENIA? ANALYSIS OF GENETIC LIABILITY AND LIFETIME CLINICAL CHARACTERISTICS
por: Dennison, Charlotte, et al.
Publicado: (2020)

Clozapine discontinuation withdrawal symptoms in schizophrenia
por: Blackman, Graham, et al.
Publicado: (2021)

What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services
por: Barnes, Thomas R. E., et al.
Publicado: (2020)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy
por: Segev, Aviv, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3fe0u6s3jbebit5qjagr0euc5q